Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway

BioSpace

After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical

PipelineRespiratoryRead full story